← Back to patent-cliff list

Milciclib maleate

Tier C — Watch / trade

Milciclib maleate

Tiziana Life Sciences Plc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type

Targets:Trk-A, CDK2

Indications (approved):Non-small cell lung cancer, 胸腺瘤, Hepatocellular carcinoma, Solid tumour

Regional status

US
Discontinued
2010-02-22
EU
Discontinued
2010-02-22
China
-
Japan
-

Synthetic routes & intermediates1 routes

Originator routes × 1Optimised (non-patent) × 0Process routes × 0

Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.

OriginatorRoute 1Steps 10 · Total yield /
PHA-848125-007802541-49-7PHA-848125-00850-01-1PHA-848125-009802534-92-5PHA-848125-010110-46-3PHA-848125-011802535-78-0PHA-848125-012—PHA-848125-001126-81-8PHA-848125-0024683-45-8PHA-848125-00317421-93-1PHA-848125-00485312-29-4PHA-848125-005802541-48-6PHA-848125-00636805-97-7PHA-848125-013802540-46-1PHA-848125-01416153-81-4API · Milciclib maleate
CodeCAS No.Intermediate
PHA-848125-007802541-49-7(Z)-ethyl 6-((dimethylamino)methylene)-1,4,4-trimethyl-7-oxo-4,5,6,7-tetrahydro-1H-indazole-3-carboxylate
PHA-848125-00850-01-1guanidine hydrochloride
PHA-848125-009802534-92-5ethyl 8-amino-1,4,4-trimethyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxylate
PHA-848125-010110-46-3Availableisopentyl nitrite
PHA-848125-011802535-78-0ethyl 8-iodo-1,4,4-trimethyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxylate
PHA-848125-012-8-iodo-1,4,4-trimethyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxylic acid
PHA-848125-001126-81-85,5-dimethylcyclohexane-1,3-dione
PHA-848125-0024683-45-83-methoxy-5,5-dimethylcyclohex-2-enone
PHA-848125-00317421-93-14,4-dimethyl-7-oxabicyclo[4.1.0]heptan-2-one
PHA-848125-00485312-29-42-methoxy-5,5-dimethylcyclohex-2-enone
PHA-848125-005802541-48-6ethyl 1,4,4-trimethyl-7-oxo-4,5,6,7-tetrahydro-1H-indazole-3-carboxylate
PHA-848125-00636805-97-71,1-di-tert-butoxy-N,N-dimethylmethanamine
PHA-848125-013802540-46-18-iodo-N,1,4,4-tetramethyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide
PHA-848125-01416153-81-44-(4-methylpiperazin-1-yl)aniline

Frequently asked questions

What are the approved indications of Milciclib maleate?

Approved indications include: Non-small cell lung cancer, 胸腺瘤, Hepatocellular carcinoma, Solid tumour.

When does the Milciclib maleate patent expire?

No public expiry year is available for Milciclib maleate yet; this page updates once verified.

How many synthesis routes are recorded for Milciclib maleate?

1 synthesis routes are recorded; the shortest is 10 steps with / total yield. Intermediates in each route carry codes and CAS numbers.

Where can I buy Milciclib maleate intermediates?

1 intermediate CAS of Milciclib maleate are available through the Unibest supply network — see the route tables on this page and request a quote per CAS.

How do I get a quote for Milciclib maleate intermediates?

Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.

Source: cross-verified data (structured fields only) · 2026-10-21